Stocktoria
ZEVRA THERAPEUTICS, INC. ZVRA
ZEVRA THERAPEUTICS, INC. (ZVRA) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $106.5M at a 78.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.645 |
| Retained earnings / assets | -1.482 |
| EBIT / assets | -0.221 |
| Equity / liabilities | 1.189 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ZVRA | ZEVRA THERAPEUTICS, INC. | 5/9 | -0.84 | 9 | +350.9% |
| ZYME | Zymeworks Inc. | 5/9 | -3.24 | — | +38.9% |
| TBPH | Theravance Biopharma, Inc. | 6/9 | 0.96 | 8.6 | +66.9% |
| URGN | UroGen Pharma Ltd. | 1/9 | -15.59 | — | +21.4% |
| GYRE | GYRE THERAPEUTICS, INC. | 3/9 | 4.52 | 71 | +10.2% |
| SIGA | SIGA TECHNOLOGIES INC | 5/9 | 16.02 | 12.1 | -31.8% |
| ASRT | Assertio Holdings, Inc. | 2/9 | -6.37 | — | -5% |
About ZEVRA THERAPEUTICS, INC.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
FAQ
Is ZVRA financially healthy?
ZEVRA THERAPEUTICS, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ZVRA pay a dividend?
No, ZEVRA THERAPEUTICS, INC. does not currently pay a dividend.
How profitable is ZVRA?
In FY2025, ZEVRA THERAPEUTICS, INC. had a net margin of 78.2% and a return on equity of 53.8%.
What is ZVRA's P/E ratio?
ZEVRA THERAPEUTICS, INC.'s trailing price-to-earnings (P/E) ratio is about 9.0×, based on its latest annual earnings.
What is the analyst price target for ZVRA?
The average Wall-Street price target for ZEVRA THERAPEUTICS, INC. is $27.89, about 143.8% above the recent price, from 9 analysts (consensus: strong buy).
Is ZVRA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ZEVRA THERAPEUTICS, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone, a P/E of about 9.0×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.